The primary aim of our team is to promote the use of the waxmoth, Galleria mellonella, as an alternative to using rodents and other mammals for scientific experimentation, in order to understand and treat infectious and congenital human disease. To facilitate its use, we are developing a comprehensive genetic, cell biological, developmental and tissue-based toolkit - including transgenic and CRISPR-based technologies. We are keen to communicate the advantages of Galleria and are actively seeking collaborative projects to further extend the capabilities of this novel and exciting model system. Here, you can read about our advances in genetic manipulation, the transgenic strains we have engineered and the protocols we have developed.
